
New Therapeutics for Novel Problems through Collaboration - Dr. Betsy O'neill
Talking Biotech with Dr. Kevin Folta
00:00
DAX Dillamab for CD 40L Diseases
DAX dillamab is an antibody-based drug that binds to a type of cells called plasma cytoid dendritic cells. PDCs produce neurons and other molecules that really help stimulate and amplify the immune response. We're testing it out in some other settings as well, including rheumatoid arthritis or kidney transplant reduction. And then we have three different clinical studies that are variations on this theme: dermatomyositis, alopecia areaada and lupus lupus.
Transcript
Play full episode